血清甲胎蛋白、肝硬化与肝细胞癌患者生存率之间的关系
Relationship between serum alpha-foetoprotein, cirrhosis and survival in hepatocellular carcinoma.
作者信息
Johnson P J, Melia W M, Palmer M K, Portmann B, Williams R
出版信息
Br J Cancer. 1981 Oct;44(4):502-5. doi: 10.1038/bjc.1981.218.
Abstract
An analysis of survival time of 57 West European patients with hepatocellular carcinoma was carried out to define which of several possible factors (age, sex, cirrhosis and raised serum alpha-foetoprotein (AFP)) influenced survival. Although survival was significantly longer in younger patients (P less than 0.02) and in patients with normal serum AFP (P less than 0.01), multivariate analysis showed that significant variation in survival time is better explained by the single factor, the presence of cirrhosis, than by AFP level. This does not seem to apply for patients with this tumour in Africa and the Far East, and there may be a fundamental difference in the natural history of the tumour between high- and low-incidence areas.
摘要
对57例西欧肝细胞癌患者的生存时间进行了分析，以确定几个可能的因素（年龄、性别、肝硬化和血清甲胎蛋白（AFP）升高）中哪些因素会影响生存。尽管年轻患者（P<0.02）和血清AFP正常的患者（P<0.01）的生存时间明显更长，但多因素分析显示，生存时间的显著差异用单一因素即肝硬化的存在来解释，比用AFP水平来解释更好。这似乎不适用于非洲和远东地区患有这种肿瘤的患者，高发病率地区和低发病率地区的肿瘤自然史可能存在根本差异。
相似文献
1
Relationship between serum alpha-foetoprotein, cirrhosis and survival in hepatocellular carcinoma.血清甲胎蛋白、肝硬化与肝细胞癌患者生存率之间的关系
Br J Cancer. 1981 Oct;44(4):502-5. doi: 10.1038/bjc.1981.218.
2
Alpha-fetoprotein production by hepatocellular carcinoma is prognostic of poor patient survival.肝细胞癌产生的甲胎蛋白预示着患者生存预后不良。
J Surg Oncol. 1992 Mar;49(3):151-5. doi: 10.1002/jso.2930490305.
3
4
5
[Hepatocellular carcinoma with cirrhosis: treatment with doxorubicin. Phase II evaluation].[伴有肝硬化的肝细胞癌：阿霉素治疗。II期评估]
Bull Cancer. 1984;71(5):442-5.
6
7
Human telomerase reverse transcriptase messenger RNA (TERT mRNA) as a tumour marker for early detection of hepatocellular carcinoma.人端粒酶逆转录酶信使核糖核酸（TERT mRNA）作为肝细胞癌早期检测的肿瘤标志物。
Arab J Gastroenterol. 2014 Jun;15(2):68-71. doi: 10.1016/j.ajg.2014.04.001. Epub 2014 Jun 10.
8
Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical use.肝癌患者甲胎蛋白水平的决定因素：对其临床应用的影响。
Cancer. 2014 Jul 15;120(14):2150-7. doi: 10.1002/cncr.28706. Epub 2014 Apr 10.
9
Results of surgical resection for hepatocellular carcinoma.肝细胞癌手术切除的结果。
Hepatogastroenterology. 1990 Apr;37(2):172-5.
10
Assessing prognostic significance of preoperative alpha-fetoprotein in hepatitis B-associated hepatocellular carcinoma: normal is not the new normal.评估术前甲胎蛋白在乙型肝炎相关性肝细胞癌中的预后意义：正常并非新的正常。
Ann Surg Oncol. 2014 Mar;21(3):986-94. doi: 10.1245/s10434-013-3357-z.
引用本文的文献
1
Translating epithelial mesenchymal transition markers into the clinic: Novel insights from proteomics.将上皮-间质转化标志物应用于临床：蛋白质组学的新见解
EuPA Open Proteom. 2016 Jan 6;10:31-41. doi: 10.1016/j.euprot.2016.01.003. eCollection 2016 Mar.
2
The mitochondrial hinge protein, UQCRH, is a novel prognostic factor for hepatocellular carcinoma.线粒体铰链蛋白UQCRH是肝细胞癌的一种新型预后因素。
Cancer Med. 2017 Apr;6(4):749-760. doi: 10.1002/cam4.1042. Epub 2017 Mar 23.
3
Development and application of a fluorescence protein microarray for detecting serum alpha-fetoprotein in patients with hepatocellular carcinoma.用于检测肝细胞癌患者血清甲胎蛋白的荧光蛋白微阵列的研发与应用
J Int Med Res. 2016 Dec;44(6):1414-1423. doi: 10.1177/0300060516672370. Epub 2016 Nov 24.
4
Upregulation of MicroRNA-19b predicts good prognosis in patients with hepatocellular carcinoma presenting with vascular invasion or multifocal disease.微小RNA-19b的上调预示着伴有血管侵犯或多灶性病变的肝细胞癌患者预后良好。
BMC Cancer. 2015 Oct 9;15:665. doi: 10.1186/s12885-015-1671-5.
5
microRNA-150: a promising novel biomarker for hepatitis B virus-related hepatocellular carcinoma.微小RNA-150：一种有前景的新型乙型肝炎病毒相关肝细胞癌生物标志物。
Diagn Pathol. 2015 Jul 28;10:129. doi: 10.1186/s13000-015-0369-y.
6
Enzymatic activity of type 1 iodothyronine deiodinase in selected liver tumors.1 型碘甲状腺原氨酸脱碘酶在选定肝肿瘤中的酶活性。
Arch Med Sci. 2014 Aug 29;10(4):801-5. doi: 10.5114/aoms.2013.34323. Epub 2013 Aug 20.
7
Serum manganese superoxide dismutase and thioredoxin are potential prognostic markers for hepatitis C virus-related hepatocellular carcinoma.血清锰超氧化物歧化酶和硫氧还蛋白可能是丙型肝炎病毒相关肝细胞癌的预后标志物。
World J Gastroenterol. 2011 Nov 28;17(44):4890-8. doi: 10.3748/wjg.v17.i44.4890.
8
MicroRNA122 is a key regulator of α-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma.微小 RNA122 是甲胎蛋白表达的关键调节因子，影响肝癌的侵袭性。
Nat Commun. 2011 Jun 7;2:338. doi: 10.1038/ncomms1345.
9
Alpha-1-acid glycoprotein as potential biomarker for alpha-fetoprotein-low hepatocellular carcinoma.α1-酸性糖蛋白作为甲胎蛋白低的肝细胞癌的潜在生物标志物。
BMC Res Notes. 2010 Nov 23;3:319. doi: 10.1186/1756-0500-3-319.
10
Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a large case cohort study.不可切除肝细胞癌的肿瘤和肝脏决定因素预后：大型病例队列研究。
Hepatol Int. 2009 Dec 24;4(1):396-405. doi: 10.1007/s12072-009-9157-7.
本文引用的文献
1
Serum alpha-feto-protein. I. Immunodiffusion and immuno-assay results in cases of primary cancer of the liver.血清甲胎蛋白。I. 原发性肝癌病例的免疫扩散和免疫测定结果
S Afr Med J. 1968 Nov 2;42(42):1138-41.
2
A clinicopathological review of 100 cases of primary malignant tumours of the liver.100例原发性肝癌的临床病理回顾
J Clin Pathol. 1974 Aug;27(8):669-82. doi: 10.1136/jcp.27.8.669.
3
Serum alpha-fetoprotein in 184 Ugandan patients with hepatocellular carcinoma. Clinical, laboratory, and histopathologic correlations.184例乌干达肝细胞癌患者的血清甲胎蛋白。临床、实验室及组织病理学相关性研究
Cancer. 1974 Apr;33(4):959-64. doi: 10.1002/1097-0142(197404)33:4<959::aid-cncr2820330410>3.0.co;2-v.
4
Radioimmunoassay of alpha-fetoprotein in primary and secondary cancer of the liver.原发性和继发性肝癌中甲胎蛋白的放射免疫测定
J Natl Cancer Inst. 1972 Sep;49(3):623-30.
5
Hepatic artery infusion chemotherapy in hepatoma.肝癌的肝动脉灌注化疗
Br Med J. 1968 Aug 10;3(5614):346-9. doi: 10.1136/bmj.3.5614.346.
6
Serum-alpha 1-fetoprotein in hepatocellular carcinoma.肝细胞癌中的血清甲胎蛋白
Lancet. 1974 Aug 10;2(7876):334-6. doi: 10.1016/s0140-6736(74)91705-x.
7
Alpha-fetoprotein concentrations measured by radioimmunoassay in diagnosing and excluding hepatocellular carcinoma.用放射免疫分析法测定甲胎蛋白浓度以诊断和排除肝细胞癌。
Br Med J. 1978 Sep 2;2(6138):661-3. doi: 10.1136/bmj.2.6138.661.
8
Induction of remission in hepatocellular carcinoma with doxorubicin.阿霉素诱导肝细胞癌缓解
Lancet. 1978 May 13;1(8072):1006-9. doi: 10.1016/s0140-6736(78)90735-3.
9
A staging system for hepatocellular carcinoma: prognostic factors in Ugandan patients.肝细胞癌分期系统：乌干达患者的预后因素
Cancer. 1975 May;35(5):1357-64. doi: 10.1002/1097-0142(197505)35:5<1357::aid-cncr2820350518>3.0.co;2-8.
Zotero 插件